Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVax + Nivolumab + Ipilimumab in Advanced Melanoma
NCT03929029Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoVax in cutaneous melanoma (CM) (2 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose-Limiting Toxicity at 7 weeks. Started Nov 2020; status: active, not recruiting.
02
Drugs
NeoVax
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03929029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929029.